Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.

@article{Montemurro2013HumanEG,
  title={Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.},
  author={Filippo Montemurro and Serena Di Cosimo and Grazia Arpino},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2013},
  volume={24 11},
  pages={2715-24}
}
Recent data show a significant benefit from combining an anti-HER-2 agent with endocrine therapy in HER2-positive and hormone receptor (HR)-positive metastatic breast cancer. However, as the clinical outcomes achieved by these combinations do not favourably match those with chemotherapy, clinicians still perceive HER2-positive breast cancer as an homogeneous group and consider chemotherapy with anti-HER2 agents as the preferred treatment option, regardless of the HR status. Indeed, in HR… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 87 references

Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer

  • LA Carey, D Berry, D Ollila
  • J Clin Oncol (Meeting Abstracts)
  • 2013
1 Excerpt

Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert reviews Annals of Oncology 

  • A Goldhirsch, WC Wood, AS Coates
  • Montemurro et al. Volume
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…